CN111171002A - Preparation method of PARP inhibitor intermediate - Google Patents
Preparation method of PARP inhibitor intermediate Download PDFInfo
- Publication number
- CN111171002A CN111171002A CN201910405969.XA CN201910405969A CN111171002A CN 111171002 A CN111171002 A CN 111171002A CN 201910405969 A CN201910405969 A CN 201910405969A CN 111171002 A CN111171002 A CN 111171002A
- Authority
- CN
- China
- Prior art keywords
- reaction
- cuprous
- preparation
- added
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000012661 PARP inhibitor Substances 0.000 title claims abstract description 6
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 129
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 95
- 239000003054 catalyst Substances 0.000 claims abstract description 29
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims abstract description 27
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims abstract description 23
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 114
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 46
- 239000012458 free base Substances 0.000 claims description 31
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 239000012046 mixed solvent Substances 0.000 claims description 14
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 238000001953 recrystallisation Methods 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 claims description 5
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 4
- 239000012973 diazabicyclooctane Substances 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- -1 azabicyclo (DBU) Chemical compound 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 claims description 2
- 229910002666 PdCl2 Inorganic materials 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims description 2
- RFKZUAOAYVHBOY-UHFFFAOYSA-M copper(1+);acetate Chemical compound [Cu+].CC([O-])=O RFKZUAOAYVHBOY-UHFFFAOYSA-M 0.000 claims description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 claims description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 claims description 2
- 229940045803 cuprous chloride Drugs 0.000 claims description 2
- 150000002940 palladium Chemical class 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- GVEOHMXXNFKHOT-UHFFFAOYSA-N 4-(nitromethyl)morpholine Chemical compound [N+](=O)([O-])CN1CCOCC1 GVEOHMXXNFKHOT-UHFFFAOYSA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 7
- MLYBNYNKVKCHHJ-MUUNZHRXSA-N methyl 6-fluoro-2-[(2R)-2-methyl-1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]pyrrolidin-2-yl]-1-(4-methylphenyl)sulfonylindole-4-carboxylate Chemical compound COC(=O)c1cc(F)cc2n(c(cc12)[C@@]1(C)CCCN1CC(=O)OC(C)(C)C)S(=O)(=O)c1ccc(C)cc1 MLYBNYNKVKCHHJ-MUUNZHRXSA-N 0.000 abstract description 4
- 239000012074 organic phase Substances 0.000 description 30
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- 238000001816 cooling Methods 0.000 description 20
- 238000001914 filtration Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000002425 crystallisation Methods 0.000 description 14
- 230000008025 crystallization Effects 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000004821 distillation Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000005191 phase separation Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 4
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229910004039 HBF4 Inorganic materials 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229950007072 pamiparib Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108091007743 BRCA1/2 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 1
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LZWLLMFYVGUUAL-UHFFFAOYSA-L ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/08—Halides
- B01J27/122—Halides of copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
-
- B01J35/19—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
- B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
- B01J2231/4266—Sonogashira-type, i.e. RY + HC-CR' triple bonds, in which R=aryl, alkenyl, alkyl and R'=H, alkyl or aryl
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
- B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
- B01J2231/4277—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues
- B01J2231/4283—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues using N nucleophiles, e.g. Buchwald-Hartwig amination
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/84—Metals of the iron group
- B01J2531/842—Iron
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
The present invention relates to a process for the preparation of a PARP inhibitor, in particular methyl (R) -2- (1- (2- (tert-butyloxy) -2-oxoethyl) -2-methylpyrrolidin-2-yl) -6-fluoro-1-tosyl-1H-indole-4-carboxylate, an intermediate of pamiprarib, using a palladium (Pd) catalyst comprising at least one or both of Pd (dppf) Cl2 and Pd (bpdtf) Cl2, and cuprous iodide (Cul). The method can improve the conversion rate of raw materials and obtain products with high chiral purity, and has the advantages of stable production, good repeatability, high yield and production cost saving in industrial mass production.
Description
Technical Field
The invention discloses a preparation method of a PARP inhibitor intermediate, and particularly relates to a preparation method of a Pamiparib intermediate (R) -2- (1- (2- (tert-butyloxy) -2-oxoethyl) -2-methylpyrrolidin-2-yl) -6-fluoro-1-tosyl-1H-indole-4-carboxylic acid methyl ester.
Background
WO2013/097225A1 discloses poly (ADP-ribosyl) transferase (PARPs) inhibitors and specifically compoundsI.e. (R) -2-fluoro-10 a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [ def]Cyclopenta [ a ]]Fluoren-4 (5H) -one, which is an Adenosine Diphosphate (ADP) nucleusInhibitors of carbohydrate polymerase (PARP) which are highly selective for PARP-1/2 and are effective in inhibiting proliferation of cell lines having the BRCA1/2 mutation or other HR deficiency, significantly induce tumor regression in a BRCA1 mutant breast cancer xenograft model at doses much lower than olaparib, have excellent DMPK properties and significant brain permeability. WO2017/032289A1 discloses (R) -2-fluoro-10 a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [ def]Cyclopenta [ a ]]Fluorene-
A process for the large-scale synthesis of 4(5H) -ketones, wherein,is an important intermediate in the preparation process of Pamiparib. In the large scale synthesis process disclosed in WO2017/032289a1,andin Pd (Ph)3)2Cl2And CuI to form the intermediateI.e. (R) -2- (1- (2- (tert-butyloxy) -2-oxoethyl) -2-methylpyrrolidin-2-yl) -6-fluoro-1-tosyl-1H-indole-4-carboxylic acid methyl ester (BG-11), however when Pd (Ph) is used3)2Cl2And CuI as a catalyst, there is a significant amount of BG-10 that cannot complete the conversion, resulting in difficult purification and poor yield.
The inventors of the present invention have found, through a large number of inventive investigations, that Pd (dppf) Cl is used2And cuprous salt is used as a catalyst, so that the problem of low conversion rate is solved, the reaction can be completed within 36 hours, only about 0.3 percent of BG-10 remains, and the conversion rate of BG-10 is greatly improved.
However, in the use of [1, 1' -bis (diphenylphosphino) ferrocene]Palladium dichloride (Pd (dppf) Cl2) And cuprous salt as catalyst, BG-10 will be partially eliminated during the reactionAnd the chiral purity of the obtained product is only about 90 percent. Additional chemical resolution operations are required in subsequent steps to achieve the desired chiral purity of the downstream drug substance (not less than 98.5%), which results in increased production costs and material loss. On the basis, through screening of various catalysts and catalytic systems, the inventor of the invention more keenly finds that 1, 1' -bis (di-tert-butylphosphino) ferrocene palladium dichloride (Pd (dtbpf) Cl2) And cuprous salt is used as a catalyst, so that the high reaction conversion rate of BG-10 can be ensured, and the chiral purity of the reaction liquid is controlled to be about 99.0 percent. After post-treatment and crystallization purification, the product with HPLC purity of more than 99.0% and chiral purity of more than 99.0% can be obtained, and the yield ranges from 65% to 85%.
Disclosure of Invention
The invention relates to a PARP inhibitor intermediate, in particular to a pamiprarib intermediateNamely (R) -methyl 2- (1- (2- (tert-butyloxy) -2-oxoethyl) -2-methylpyrrolidin-2-yl) -6-fluoro-1-tosyl-1H-indole-4-carboxylate (i.e. BG-11), comprising the steps of:
reacting BG-10 with BG-5 in an organic solvent to obtain BG-11;
the reaction is carried out using a palladium (Pd) catalyst and a cuprous salt,
the palladium catalyst at least comprises Pd (dppf) Cl2And Pd (dtbpf) Cl2One or two of them.
Preferably, the palladium catalyst comprises Pd (dtbpf) Cl2。
Optionally, the palladium catalyst may also optionally comprise Pd (PPh)3)2Cl2Pd (dibenzylideneacetone) Cl2P (cyclohexyl)3、PPh3、BINAP、P(n-Bu)3、P(t-Bu)3In dtbpfOne or more ligands, and/or Pd (OAc)2、PdCl2And any combination of one or more palladium salts.
Preferably, the palladium catalyst is Pd (dpPf) Cl2。
More preferably, the palladium catalyst is Pd (dtbpf) Cl2。
The cuprous salt may be selected from the group including, but not limited to, cuprous iodide, cuprous bromide, cuprous chloride, cuprous acetate, cuprous triflate, and any combination thereof.
Preferably, the organic solvent may be selected from the group including, but not limited to: dimethyl sulfoxide (DMSO), N-Dimethylformamide (DMF), Dimethylacetamide (DMAC), N-methylpyrrolidone (NMP), toluene, Tetrahydrofuran (THF), 2-methyltetrahydrofuran (MeTHF), acetonitrile, dioxane, and any combination thereof.
Preferably, the mole ratio of BG-10 to BG-5 is 1: 0.8-1: 3; preferably 1: 0.9-1: 2; more preferably 1: 1 to 1: 1.5; even more preferably 1: 1.2 to 1: 1.4.
Preferably, the mole ratio of BG-10 to the palladium catalyst is 1: 0.01-1: 0.1; preferably: 1: 0.05-1: 0.1; more preferably 1: 0.05-1: 0.08.
Preferably, BG-10 is reacted with Pd (dpPf) Cl2The molar ratio of (A) to (B) is 1: 0.01-1: 0.1; preferably: 1: 0.05-1: 0.1; more preferably 1: 0.05-1: 0.08.
Preferably, BG-10 and Pd (dtbpf) Cl are mentioned2The molar ratio of (A) to (B) is 1: 0.01-1: 0.1; preferably: 1: 0.05-1: 0.1; more preferably 1: 0.05-1: 0.08.
Preferably, the weight-volume ratio (M/V, g/ml) of BG-10 to the organic solvent is 1: 1-1: 10, preferably 1: 1-1: 6; more preferably 1: 2; 1: 3; 1: 4 and 1: 5.
Preferably, the mole ratio of BG-10 to cuprous salt is 1: 0.01-1: 0.1; more preferably: 1: 0.05-1: 0.1; the most preferable ratio is 1: 0.05-1: 0.08.
Preferably, an alkaline substance is also used in the reaction. The basic material is selected from the group consisting of, but not limited to, Diisopropylethylamine (DIPEA), triethylamine, pyridine, tetramethylguanidine, azomethine morpholine, potassium carbonate, sodium carbonate, potassium phosphate, cesium carbonate, triethylenediamine (DABCO), 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), and any combination thereof; more preferably, the composition comprises a compound selected from the group consisting of diisopropylethylamine, cesium carbonate, triethylenediamine (DABCO), 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), tetramethylguanidine, and any combination thereof.
Preferably, the mole ratio of BG-10 to the alkaline substance is 1: 0.5-1: 6; preferably 1: 0.8-1: 4; the most preferable ratio is 1: 1-1: 3.
Preferably, the reaction is carried out in a reaction kettle. More preferably, the reaction kettle is replaced by nitrogen.
Preferably, the reaction temperature is 50-100 ℃, preferably 60-85 ℃, more preferably 70-80 ℃, and most preferably 75-80 ℃.
Preferably, the reaction time is 1 to 48 hours, preferably 5 to 40 hours, and more preferably 12 to 30 hours.
Preferably, the temperature is reduced to 15-30 ℃ after the reaction, and preferably the temperature is reduced to room temperature.
Preferably, BG-5 is a free base.
The method further comprises the step of preparing BG-5 free base: the BG-5 salt compound is treated with a base to obtain the free base of BG-5.
The base includes but is not limited to potassium hydroxide, sodium hydroxide, ammonia, sodium carbonate, sodium bicarbonate, potassium carbonate, ammonium bicarbonate.
Preferably, this step is carried out in a mixed solution of n-heptane and water. Preferably, the preparation of BG-5 free base comprises the steps of: suspending BG-5 salt in a mixed solvent of n-heptane and water, and adding an alkaline solution to the above mixed solution to carry out a reaction, thereby obtaining the BG-5 free base.
The specific operation of the reaction is as follows: stirring, reacting, standing for layering, collecting an organic phase, washing with water, and filtering to remove insoluble substances; the organic phase is concentrated and azeotropically dewatered, and N, N-Dimethylformamide (DMF) is added to continue to distill off the remaining N-heptane, yielding a DMF solution of BG-5 free base.
Preferably, after the reaction, the method of the present invention further comprises the steps of purification and recrystallization.
The method of the present invention further comprises the step of recrystallizing the BG-11 obtained.
Preferably, said recrystallization is carried out in an alcoholic solvent. More preferably, the recrystallization is carried out in methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol. Even more preferably, said recrystallization is carried out in methanol.
The method has the advantages of stable production, good repeatability and high yield, does not need additional splitting operation in subsequent steps, saves the production cost in industrial mass production, and has good economic value.
Detailed Description
Experimental example-screening of catalyst
The following is intended to be illustrative and is intended to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for within the knowledge of one skilled in the art. Unless otherwise specified, temperatures are in degrees Celsius.
The compounds BG-5 and BG-10 used hereinafter were synthesized according to the method disclosed in WO2017/032289A1, the entire content of which is incorporated herein by reference.
Experimental example 1
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to a reactor, then N, N-dimethylformamide (25 mL) was added, the reactor was purged with nitrogen, then cuprous iodide (0.746mmol, 0.06eq.) and Pd (dppf) Cl were added2(0.746mmol, 0.06 eq.). Heating the reaction system to 75-80 ℃, and stirring for reaction for 15 hours. After the reaction is finished, cooling the reaction system to room temperature.
Wherein eq (equivalent) refers to the molar ratio of other substances based on the main raw material (set to 1eq.), and the molar ratio of the raw material CuI to the main raw material BG-10 is 0.06: 1, for example, the raw material CuI is 0.06eq.
The intermediate impurity BG-11A is generated when the reaction is in progress, and the impurity is one of important indexes needing to be monitored in a central control link. The experimental conversion rate was intermediately controlled using Agilent HPLC (high performance liquid chromatography), taking into account the content percentages of the raw material BG-10, the intermediate impurity BG-11A remaining in the reaction solution, and the product BG-11 (i.e. the intermediate control result). After reacting for 12-120 hours, cooling to below 50 ℃, taking about 0.2mL of reaction liquid, adding acetonitrile/water (volume ratio is 8/2) for dissolving, and carrying out HPLC sample injection test. All chromatographic peaks above the limit of detection were integrated and the percentage of the corresponding compound HPLC peak area was read.
The chiral purity of BG-11 in the reaction solution was tested by HPLC using a chiral liquid chromatography column: reacting for a period of time, cooling to below 50 ℃, taking about 0.2ml of reaction liquid, adding ethanol for dissolving, adopting HPLC sample injection test loaded with a chiral liquid chromatographic column, integrating the product BG-11 and the corresponding isomer thereof, and calculating the percentage of the two respectively.
The control result is as follows: BG-10/BG-11A/BG-11 ═ 0.3%/0.8%/88.2%, chiral purity by HPLC was 90.1%.
In order to further improve the purity of BG-11, the following operations are still required: adding 30-50 g of methyl tert-butyl ether and 50-60 g of water, stirring, standing for layering, stirring the organic phase for a period of time, standing for layering, removing the water phase, and washing the organic phase with water. The organic phase was washed twice with 15-25 g of 10% aqueous thiourea solution and then filtered through silica gel. And (3) carrying out reduced pressure distillation on the filtrate, carrying out solvent replacement by using 10-30 g of n-heptane, adding 8-10 g of ethyl acetate to obtain an n-heptane/ethyl acetate solution of the BG-11 crude product, carrying out decolorization and secondary silica gel column treatment, concentrating the filtrate, and carrying out solvent replacement by using 10-15 g of ethyl acetate. The resulting solution of BG-11 in ethyl acetate (96% HPLC purity, 92.1% chiral purity, 68% yield) was used directly in the next step.
Experimental example 2
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (PPh) were added3)2Cl2(0.746mmol, 0.06 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 2 was obtained as follows: BG-10/BG-11A/BG-11 ═ 31.6%/5.9%/50.4%, chiral purity by HPLC 97.1%.
Experimental example 3
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (dppf) Cl were added2(0.746mmol, 0.06eq.) and PPh3(1.491mmol, 0.12 eq). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 3 was obtained as follows: BG-10/BG-11A/BG-11 ═ 0.1%/2.6%/81.1%, chiral purity by HPLC was 91.4%.
Experimental example 4
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (dppf) Cl were added2(0.249mmol, 0.02eq.) and Pd (PPh)3)2Cl2(0.249mmol, 0.02 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 4 was obtained as follows: BG-10/BG-11A/BG-11 ═ 2.9%/2.1%/85.2%, chiral purity by HPLC 93.1%.
Experimental example 5
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (dibenzylideneacetone) Cl were added2(Pd(dibenzalacetone)Cl2) (0.746mmol, 0.06 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 5 was obtained as follows: BG-10/BG-11A/BG-11 ═ 92.7%/0%/0.5%, chiral purity by HPLC was not determined.
Experimental example 6
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to a reaction vessel followed by N, N-dimethylformamide (25 ml). The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (PPh) were added3)4(0.746mmol, 0.06 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 6 was obtained as follows: BG-10/BG-11A/BG-11 ═ 46.9%/8.6%/26.6%, chiral purity by HPLC 98.8%.
Experimental example 7
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (dtbpf) Cl were added2(0.746mmol, 0.06 eq.)). The reaction system is heated to 75-80 DEG CThe reaction was stirred for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 7 was obtained as follows: BG-10/BG-11A/BG-11 ═ 2.6%/3.1%/82.6%, chiral purity by HPLC 99.0%.
Experimental example 8
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (OAc) were added2(0.746mmol, 0.06eq.), P (cyclohexyl)3(P(cyclohexyl)3) (1.491mmol, 0.12 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 8 was obtained as follows: BG-10/BG-11A/BG-11 ═ 80.3%/2.6%/9.8%, chiral purity by HPLC 88.1%.
Experimental example 9
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (OAc) were added2(0.746mmol, 0.06eq.), BINAP (0.746mmol, 0.06 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 9 was obtained as follows: BG-10/BG-11A/BG-11 ═ 83.8%/2.1%/9.7%, chiral purity by HPLC 96.4%.
Experimental example 10
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction kettle is subjected to nitrogen replacement, and thenCuprous iodide (0.746mmol, 0.06eq.) and Pd (OAc) were added2(0.746mmol,0.06eq.),P(Bu)3(1.491mmol, 0.12 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 10 was obtained as follows: BG-10/BG-11A/BG-11 ═ 90.4%/0%/1.0%, and the yield of BG-11 was too low to measure the chiral purity by HPLC.
Experimental example 11
The compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (OAc) were added2(0.746mmol,0.06eq.),PPh3(1.491mmol, 0.12 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 11 was obtained as follows: BG-10/BG-11A/BG-11 ═ 39.5%/4.8%/43.1%, chiral purity by HPLC 96.0%.
Experimental example 12
Compound BG-10(5.0g, 1.491mmol, 0.12eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (OAc) were added2(0.746mmol, 0.06eq.), dtbpf (0.746mmol, 0.06 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 12 was obtained as follows: BG-10/BG-11A/BG-11 ═ 11.8%/0.8%/75.3%, chiral purity by HPLC 98.9%.
Experimental example 13
Compound BG-10(5.0g, 12.43mmol, 1eq.), BG-5 free base (14.91mmol, 1.2eq.) and tetramethylguanidine (37.29mmol, 3eq.) were added to the reaction vessel followed by 25mL of N, N-dimethylformamide. The reaction vessel was purged with nitrogen, and then cuprous iodide (0.746mmol, 0.06eq.) and Pd (OAc) were added2(0.746mmol,0.06eq.),P(t-Bu)3(0.746mmol, 0.06 eq.). The reaction system is heated to 75-80 ℃ and stirred for reaction for 15 hours. After the reaction is finished, the temperature is reduced to room temperature.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 13 was obtained as follows: BG-10/BG-11A/BG-11 ═ 27.9%/3.4%/59.2%, chiral purity by HPLC 99.0%.
Experimental example 14
The compound BG-10(1.0g, 2.49mmol, 1eq.), BG-5 free base (3.49mmol, 1.4eq.) and Diisopropylethylamine (DIPEA) (7.47mmol, 3eq.) were added to the reaction vessel followed by 4mL of N, N-dimethylformamide. The autoclave was purged with nitrogen, and then cuprous iodide (0.149mmol, 0.06eq.) and Pd (OAc) were added2(0.149mmol,0.06eq.),P(t-Bu)3HBF4(0.149mmol, 0.06eq.) and reacted at 60 ℃ for 17 hours. The reaction system is heated to 80 ℃ and stirred for reaction for 48 hours. After the reaction was completed, a sample was taken for central control testing.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 14 was obtained as follows: BG-10/BG-11A/BG-11 ═ 31.65%/0%/50.66%.
Experimental example 15
The compound BG-10(1.0g, 2.49mmol, 1eq.), BG-5 free base (3.49mmol, 1.4eq.) and azabicyclo (DBU) (7.47mmol, 3eq.) were added to the reaction vessel followed by 4mL of N, N-dimethylformamide. The autoclave was purged with nitrogen, and then cuprous iodide (0.149mmol, 0.06eq.) and Pd (OAc) were added2(0.149mmol,0.06eq.),P(t-Bu)3HBF4(0.149mmol, 0.06eq.) and reacted at 60 ℃ for 17 hours. The reaction system is heated to 80 ℃ and stirred for reaction for 48 hours. After the reaction was completed, a sample was taken for central control testing.
Then, intermediate control and test were performed in the same manner as in experimental example 1, and the control result of experimental example 15 was obtained as follows: BG-10/BG-11A/BG-11 ═ 0%/1.41%/54.30%.
TABLE 1 results of catalyst screening
As can be seen from the screening results, when Pd (PPh) is used3)2Cl2、Pd(dibenzalacetone)Cl2And Pd (PPh)3)4、Pd(OAc)2(use Pd (OAc)2Used together with a phosphine ligand when used as a catalyst), etc., a large amount of BG-10 is present and cannot be converted into BG-11. Pd (PPh) was used as in Experimental example 23)2Cl2As a catalyst, 31.6% of BG-10 was not converted, and the controlled conversion of BG-10 was 50.4%. When Pd (dppf) Cl is used2And/or Pd (dtbpf) Cl2When used as a catalyst, the conversion rate of BG-10 can be greatly improved, and Pd (dppf) Cl is used in examples 1 and 32The balance of BG-10 was only 0.3% and 0.1%; using Pd (dtbpf) Cl2The remaining amount of the catalyst BG-10 was only 2.6%.
Although Pd (dppf) Cl was used2When the catalyst is used as a catalyst, the conversion rate of BG-10 is high, but the chiral purity of the obtained BG-11 is only 90.1% (Experimental example 1), and the purity cannot be directly used for the next drug production, and the chiral purity needs to be improved by chemical resolution in the subsequent production steps.
And Pd (dtbpf) Cl is used2The experimental example 7 as the catalyst has higher BG-10 conversion rate, the chiral purity of the reaction product BG-11 in the step can reach 99.0 percent, and the step of chemical resolution can be omitted, so that the production cost is reduced.
Example 1
64.0g of BG-5 salt (105mmol, 1.4eq.) was suspended in a mixed solvent composed of 150mL of n-heptane and 60mL of water to form a suspension, and the temperature of the suspension was lowered to 5 ℃. 23.4g of potassium hydroxide was dissolved in 75mL of water, added to the suspension, stirred for 2 hours, and then warmed to room temperature.Standing for phase separation, collecting an organic phase, washing the organic phase with water, and filtering to remove insoluble substances. The resulting organic phase was concentrated, azeotroped and water removed, then 60mL of N, N-Dimethylformamide (DMF) was added and the distillation continued to remove the remaining N-heptane to give a solution of BG-5 free base in N, N-dimethylformamide. The BG-5 solution was transferred to a reaction kettle and then 30.0g of BG-10(75mmol, 1.0eq.), 25.8g of tetramethylguanidine and 60mL of N, N-dimethylformamide were added. The reaction vessel was purged with nitrogen, and then cuprous iodide (4.5mmol, 0.060eq.) and Pd (dtbpf) Cl were added2(4.5mmol, 0.060 eq.). The reaction was warmed to 80 ℃ and the reaction mixture was stirred for 22 hours. After the reaction is finished, cooling to room temperature, and then adding 200-250 g of methyl tert-butyl ether and 250-300 g of water. After stirring for a while, the mixture was allowed to stand to separate the aqueous phase and the organic phase was washed with water. The organic phase is washed with 120-160 g of a mixed aqueous solution containing 5% thiourea and 5% sodium chloride, and then filtered through silica gel. And carrying out reduced pressure distillation on the filtrate, supplementing 150-180 g of n-heptane, and then filtering by using silica gel. The filtrate was distilled under reduced pressure, and then methanol was added for solvent exchange. Heating to dissolve the solid generated in the system, then cooling to 40 ℃, adding crystal seeds BG-11 to induce crystallization, slowly adding water to fully separate out the product, and then cooling to 5 ℃. The solid is collected by filtration, washed by a methanol/water mixed solvent and dried in vacuum at 40-45 ℃ to obtain the product BG-11 (the HPLC purity is 99.8%, the chiral purity is 99.3%, and the control result is that BG-10/BG-11A/BG-11 is 0%/3.6%/81.3%, the raw material BG-10 is completely converted, the residual intermediate BG-11A is 3.6%, BG-11 is 81.3%, and the yield is 75.1%).
Example 2
64.0g of BG-5 salt (105mmol, 1.4eq.) was suspended in a mixed solvent consisting of 150mL of n-heptane and 45mL of water and cooled to 5 ℃. 23.4g of potassium hydroxide was dissolved in 120mL of water, added to the suspension, stirred for 2 hours, and then warmed to room temperature. Standing for phase separation, collecting organic phase, washing with water, and filtering to remove insoluble substances. The resulting organic phase was concentrated to remove water azeotropically, then 90mL of N, N-Dimethylformamide (DMF) was added and the remaining N-heptane was distilled off to give a solution of BG-5 free base in N, N-dimethylformamide. BG-The 5 solution was transferred to a reaction kettle, and then 30.0g of BG-10(75mmol, 1.0eq.), 25.8g of tetramethylguanidine and 90mL of a solution of N, N-dimethylformamide were added. The reaction vessel was purged with nitrogen, and then cuprous iodide (4.5mmol, 0.060eq.) and Pd (dtbpf) Cl were added2(4.5mmol, 0.060 eq.). The reaction system is heated to 80 ℃ and stirred for reaction for 24 hours. After the reaction is finished, cooling to room temperature, and then adding 200-250 g of methyl tert-butyl ether and 250-300 g of water. After stirring for a while, the mixture was allowed to stand to separate the aqueous phase and the organic phase was washed with water. The separated organic phase was washed with 120 to 160g of a mixed aqueous solution containing 5% thiourea and 5% sodium chloride, and then filtered through silica gel. And carrying out reduced pressure distillation on the filtrate, supplementing 150-180 g of n-heptane, and then filtering by using silica gel. The filtrate was distilled under reduced pressure, and then methanol was added for solvent exchange. Distilling the mixture, heating up the solid generated in the dissolution system, then cooling to 40-45 ℃ for crystallization, adding crystal seeds BG-11 for induced crystallization, slowly adding water to fully separate out the product, and then cooling to 5 ℃. The solid was collected by filtration, washed with a mixed solvent of methanol/water, and dried in vacuo at 45 ℃ to give BG-11 (chiral purity 99.53%, yield 68.28%) as a product.
Example 3
64.0g of BG-5 salt (105mmol, 1.4eq.) was suspended in a mixed solvent consisting of 150mL of n-heptane and 60mL of water and the temperature was reduced to 5 ℃. 23.4g of potassium hydroxide was dissolved in 120mL of water, added to the suspension, stirred for 2 hours, and then warmed to room temperature. Standing for phase separation, collecting organic phase, washing with water, and filtering to remove insoluble substances. The resulting organic phase was concentrated to remove water azeotropically, then 60mL of N, N-Dimethylformamide (DMF) was added and the remaining N-heptane was distilled off to give a solution of BG-5 free base in N, N-dimethylformamide. The BG-5 solution was transferred to a reaction kettle and then 30.0g of BG-10(75mmol, 1.0eq.), 25.8g of tetramethylguanidine and 60mL of N, N-dimethylformamide were added. The reactor was purged with nitrogen, and then cuprous iodide (4.5mmol, 0.060eq.) and Pd (dtbpf) Cl2(6.0mmol, 0.080eq.) were added. The reaction system was heated to 80 ℃ and stirred for 22 hours. After the reaction is finished, cooling to room temperature, and then adding 200-250 g of methyl tert-butyl ether and 250-300 g of water. After stirring for a while, the mixture was allowed to stand to separate the aqueous phase and the organic phase was washed with water. The separated organic phase was washed with 120 to 160g of a mixed aqueous solution containing 5% thiourea and 5% sodium chloride, and then filtered through silica gel. And carrying out reduced pressure distillation on the filtrate, supplementing 150-180 g of n-heptane, and then filtering by using silica gel. The filtrate was distilled under reduced pressure, and then methanol was added for solvent exchange. Distilling the mixture, heating up the solid generated in the dissolution system, cooling to 40-45 ℃ for crystallization, adding crystal seeds BG-11 for induced crystallization, slowly adding water to fully separate out the product, and cooling to 5 ℃. The solid was collected by filtration, washed with a mixed solvent of methanol/water, and dried under vacuum at 45 ℃ to obtain BG-11 (chiral purity 99.43%, yield 76.98%).
Example 4
64.0g of BG-5 salt (105mmol, 1.4eq.) was suspended in a mixed solvent consisting of 150mL of n-heptane and 60mL of water and the temperature was reduced to 5 ℃. 23.4g of potassium hydroxide was dissolved in 120mL of water, added to the suspension, stirred for 2 hours, and then warmed to room temperature. Standing for phase separation, collecting organic phase, washing with water, and filtering to remove insoluble substances. The resulting organic phase was concentrated to remove water azeotropically, then 60mL of N, N-Dimethylformamide (DMF) was added and the remaining N-heptane was distilled off to give a solution of BG-5 free base in N, N-dimethylformamide. The BG-5 solution was transferred to a reaction kettle and then 30.0g of BG-10(75mmol, 1.0eq.), 25.8g of tetramethylguanidine and 60mL of N, N-dimethylformamide were added. The reaction vessel was purged with nitrogen, and then cuprous iodide (3.75mmol, 0.050eq.) and Pd (dtbpf) Cl were added2(4.5mmol, 0.060 eq.). The reaction system was heated to 80 ℃ and stirred for 22 hours. After the reaction is finished, cooling to room temperature, and then adding 200-250 g of methyl tert-butyl ether and 250-300 g of water. After stirring for a while, the mixture was allowed to stand to separate the aqueous phase and the organic phase was washed with water. The separated organic phase was washed with 120 to 160g of a mixed aqueous solution containing 5% thiourea and 5% sodium chloride, and then filtered through silica gel. And carrying out reduced pressure distillation on the filtrate, supplementing 150-180 g of n-heptane, and then filtering by using silica gel. The filtrate was distilled under reduced pressure, and then methanol was added for solvent exchange. Distilling the mixture, heating up the solid generated in the dissolution system, then cooling to 40-45 ℃ for crystallization, adding crystal seed BG-11 for inducing crystallization, and slowly addingWater is used for fully separating out the product, and then the temperature is reduced to 5 ℃. The solid was collected by filtration, washed with a mixed solvent of methanol/water, and dried in vacuo at 45 ℃ to give BG-11 (chiral purity 99.50%, yield 69.93%).
Example 5
64.0g of BG-5 salt (105mmol, 1.4eq.) was suspended in a mixed solvent consisting of 150mL of n-heptane and 60mL of water and cooled to 5 ℃. 23.4g of potassium hydroxide was dissolved in 120mL of water, added to the suspension, stirred for 2 hours, and then warmed to room temperature. Standing for phase separation, collecting organic phase, washing with water, and filtering to remove insoluble substances. The resulting organic phase was concentrated to remove water azeotropically, then 60mL of N, N-Dimethylformamide (DMF) was added and the remaining N-heptane was distilled off to give a solution of BG-5 free base in N, N-dimethylformamide. The BG-5 solution was transferred to a reaction kettle and then 30.0g of BG-10(75mmol, 1.0eq.), 25.8g of tetramethylguanidine and 60mL of N, N-dimethylformamide were added. The reaction vessel was purged with nitrogen, and then cuprous iodide (4.5mmol, 0.060eq.) and Pd (dtbpf) Cl were added2(4.5mmol, 0.060 eq.). The reaction system is heated to 80 ℃ and stirred for reaction for 24 hours. After the reaction is finished, cooling to room temperature, and then adding 200-250 g of methyl tert-butyl ether and 250-300 g of water. After stirring for a while, the mixture was allowed to stand to separate the aqueous phase and the organic phase was washed with water. The separated organic phase was washed with 120 to 160g of a mixed aqueous solution containing 5% thiourea and 5% sodium chloride, and then filtered through silica gel. And carrying out reduced pressure distillation on the filtrate, supplementing 150-180 g of n-heptane, and then filtering by using silica gel. The filtrate was distilled under reduced pressure, and then methanol was added for solvent exchange. Distilling the mixture, heating up the solid generated in the dissolution system, then cooling to 40-45 ℃ for crystallization, adding crystal seeds BG-11 for induced crystallization, slowly adding water to fully separate out the product, and then cooling to 3 ℃. The solid was collected by filtration, washed with a mixed solvent of methanol/water, and dried in vacuo at 45 ℃ to give BG-11 (chiral purity 99.32%, yield 75.01%) as a product.
Example 6
64.0g of BG-5 salt (105mmol, 1.4eq.) was suspended in a mixed solvent of 150mL of n-heptane and 60mL of water and cooled to 5 ℃. 23.4g of potassium hydroxide was dissolved in 120mL of water, and addedThe suspension was stirred for 2 hours and then warmed to room temperature. Standing for phase separation, collecting organic phase, washing with water, and filtering to remove insoluble substances. The resulting organic phase was concentrated to remove water azeotropically, then 60mL of N, N-Dimethylformamide (DMF) was added and the remaining N-heptane was distilled off to give a solution of BG-5 free base in N, N-dimethylformamide. The BG-5 solution was transferred to a reaction kettle and then 30.0g of BG-10(75mmol, 1.0eq.), 25.8g of tetramethylguanidine and 60mL of N, N-dimethylformamide were added. The reaction vessel was purged with nitrogen, and then cuprous iodide (4.5mmol, 0.060eq.) and Pd (dtbpf) Cl were added2(4.5mmol, 0.060 eq.). The reaction system is heated to 80 ℃ and stirred for reaction for 24 hours. After the reaction is finished, cooling to room temperature, and then adding 200-250 g of methyl tert-butyl ether and 250-300 g of water. After stirring for a while, the mixture was allowed to stand to separate the aqueous phase and the organic phase was washed with water. The separated organic phase was washed with 120 to 160g of a mixed aqueous solution containing 5% thiourea and 5% sodium chloride, and then filtered through silica gel. And carrying out reduced pressure distillation on the filtrate, supplementing 150-180 g of n-heptane, and then filtering by using silica gel. The filtrate was distilled under reduced pressure, and then methanol was added for solvent exchange. Distilling the mixture, heating up the solid generated in the dissolution system, then cooling to 35-45 ℃ for crystallization, adding crystal seeds BG-11 for induced crystallization, slowly adding water to fully separate out the product, and then cooling to 5 ℃. The solid was collected by filtration, washed with a mixed solvent of methanol/water, and dried in vacuo at 45 ℃ to give BG-11 (chiral purity 99.35%, yield 67.69%).
It is noted that BG-11 seeds can be prepared according to any of the methods described in the examples (without the addition of seeds). The crystal form is prepared in small batches for the first time without crystal seeds, and the products in the previous batches can be used as the crystal seeds for subsequent preparation and production. The seeding is mainly used for better controlling the crystallization process, so that the product is stably separated out and prevented from being separated out. Seeding is not an essential operation, and crystallization can be carried out without seeding to obtain the required crystals.
The invention has been described in detail with respect to the general description, specific embodiments and experiments, and it is intended that all modifications and improvements made without departing from the spirit of the invention are within the scope of the invention as claimed. All cited references are incorporated by reference in their entirety into this application.
Claims (10)
1. A preparation method of PARP inhibitor intermediate has a structure shown in formula (I),
the preparation method comprises the following steps: reacting BG-10 with BG-5 in an organic solvent to obtain an intermediate represented by formula (I);
characterized in that the reaction is carried out using a palladium catalyst [ Pd ]]And a cuprous salt, said palladium catalyst comprising at least Pd (dpPf) Cl2And Pd (dtbpf) Cl2One or two of them; preferably, the palladium catalyst comprises Pd (dppf) Cl2(ii) a Or preferably, the palladium catalyst comprises Pd (dtbpf) Cl2。
2. The method of claim 1, wherein the palladium catalyst further comprises Pd (PPh)3)2Cl2Pd (dibenzylideneacetone) Cl2(ii) a Or P (cyclohexyl)3、PPh3、BlNAP、P(n-Bu)3、P(t-Bu)3One or more ligands of dtbpf, and/or Pd (OAc)2、PdCl2And the like, one or more palladium salts.
3. The production method according to any one of claims 1 to 2, the organic solvent being selected from: dimethyl sulfoxide (DMSO), N-Dimethylformamide (DMF), N-Dimethylacetamide (DMAC), N-methylpyrrolidone (NMP), toluene, Tetrahydrofuran (THF), 2-methyltetrahydrofuran (MeTHF), acetonitrile, dioxane, and any combination thereof; the cuprous salt is selected from cuprous iodide, cuprous bromide, cuprous chloride, cuprous acetate, cuprous trifluoromethanesulfonate and any combination thereof.
4. The preparation method according to any one of claims 1 to 3, wherein the mole ratio of BG-10 to BG-5 is 1: 0.8-1: 3; preferably 1: 0.9-1: 2; more preferably 1: 1 to 1: 1.5; even more preferably 1: 1.2-1: 1.4; and/or the mole ratio of BG-10 to the palladium catalyst is 1: 0.01-1: 0.1; preferably: 1: 0.05-1: 0.1; more preferably 1: 0.05-1: 0.08.
5. The process according to any one of claims 1 to 4, wherein the palladium catalyst is Pd (dpPf) Cl2Or Pd (dtbpf) Cl2(ii) a BG-10 and Pd (dPPf) Cl2The molar ratio of (A) to (B) is 1: 0.01-1: 0.1; preferably: 1: 0.05-1: 0.1; more preferably 1: 0.05-1: 0.08; preferably, BG-10 and Pd (dtbpf) Cl are mentioned2The molar ratio of (A) to (B) is 1: 0.01-1: 0.1; more preferably: 1: 0.05-1: 0.1; the most preferable ratio is 1: 0.05-1: 0.08.
6. The preparation method according to any one of claims 1 to 5, wherein the weight-to-volume ratio (M/V, g/mL) of BG-10 to the organic solvent is 1: 1 to 1: 10, preferably 1: 1 to 1: 6; more preferably 1: 2; 1: 3; 1: 4 and 1: 5; and/or the mole ratio of BG-10 to cuprous salt is 1: 0.01-1: 0.1; more preferably: 1: 0.05-1: 0.1; the most preferable ratio is 1: 0.06-1: 0.08.
7. The production method according to any one of claims 1 to 6, wherein a basic substance is further used in the reaction; the basic substance is selected from the group consisting of diisopropylethylamine (DlPEA), Triethylamine (TEA), pyridine, Tetramethylguanidine (TMG), Nitromethylmorpholine (NMP), potassium carbonate, sodium carbonate, potassium phosphate, cesium carbonate, triethylenediamine (DABCO), 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), and any combination thereof; more preferably selected from Diisopropylethylamine (DIPEA), cesium carbonate, triethylenediamine (DABCO), azabicyclo (DBU), Tetramethylguanidine (TMG), and any combination thereof; the mole ratio of BG-10 to the alkaline substance is 1: 0.5-1: 6; preferably 1: 0.8-1: 4; the most preferable ratio is 1: 1-1: 3.
8. The production method according to any one of claims 1 to 7, wherein the reaction is carried out in a reaction tank; more preferably, the reaction kettle is replaced by nitrogen; the reaction temperature is 50-100 ℃, preferably 60-85 ℃, more preferably 70-80 ℃, and most preferably 75-80 ℃; the reaction time is 1-48 hours, preferably 5-40 hours, and more preferably 12-30 hours; preferably, the temperature is reduced to 15-30 ℃ after the reaction, and preferably the temperature is reduced to room temperature.
9. The preparation method according to any one of claims 1 to 8, further comprising the step of preparing BG-5 free base: treating BG-5 salt with a base to obtain the free base of BG-5; preferably, this step is carried out in a mixed solution of n-heptane and water; preferably, the preparation of BG-5 free base comprises the steps of: the BG-5 salt is suspended in a mixed solvent of n-heptane and water, and an alkaline solution is added to the above mixed solution to perform a reaction, thereby obtaining the BG-5 free base.
10. The preparation method according to any one of claims 1 to 9, further comprising the steps of purification and recrystallization, preferably the recrystallization is carried out in an alcoholic solvent, preferably the recrystallization is carried out in methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol; more preferably said recrystallization is carried out in methanol.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110525007.5A CN113402502B (en) | 2019-05-16 | 2019-05-16 | Material combination system for preparing PARP inhibitor intermediate |
CN201910405969.XA CN111171002B (en) | 2019-05-16 | 2019-05-16 | Preparation method of PARP inhibitor intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910405969.XA CN111171002B (en) | 2019-05-16 | 2019-05-16 | Preparation method of PARP inhibitor intermediate |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110525007.5A Division CN113402502B (en) | 2019-05-16 | 2019-05-16 | Material combination system for preparing PARP inhibitor intermediate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111171002A true CN111171002A (en) | 2020-05-19 |
CN111171002B CN111171002B (en) | 2021-04-06 |
Family
ID=70622376
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110525007.5A Active CN113402502B (en) | 2019-05-16 | 2019-05-16 | Material combination system for preparing PARP inhibitor intermediate |
CN201910405969.XA Active CN111171002B (en) | 2019-05-16 | 2019-05-16 | Preparation method of PARP inhibitor intermediate |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110525007.5A Active CN113402502B (en) | 2019-05-16 | 2019-05-16 | Material combination system for preparing PARP inhibitor intermediate |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN113402502B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115138396A (en) * | 2021-03-30 | 2022-10-04 | 百济神州(苏州)生物科技有限公司 | Catalyst system for Sonogashira coupling reaction and in-situ ring closing reaction |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106220635A (en) * | 2011-12-31 | 2016-12-14 | 百济神州有限公司 | As the Fourth Ring condensed of PARP inhibitor or the dihydro diaza * at five rings carbazole ketone |
CN107922425A (en) * | 2015-08-25 | 2018-04-17 | 百济神州有限公司 | Method for preparing PARP inhibitor, crystal form and application thereof |
WO2018157794A1 (en) * | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6321821B2 (en) * | 2014-04-14 | 2018-05-09 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドShanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2,3,4,6-4-substituted benzene-1,5-diamine derivatives, their production and use in pharmaceuticals |
KR20170044184A (en) * | 2014-08-27 | 2017-04-24 | 시오노기세야쿠 가부시키가이샤 | Azaindole derivative having ampk-activating effect |
-
2019
- 2019-05-16 CN CN202110525007.5A patent/CN113402502B/en active Active
- 2019-05-16 CN CN201910405969.XA patent/CN111171002B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106220635A (en) * | 2011-12-31 | 2016-12-14 | 百济神州有限公司 | As the Fourth Ring condensed of PARP inhibitor or the dihydro diaza * at five rings carbazole ketone |
CN107922425A (en) * | 2015-08-25 | 2018-04-17 | 百济神州有限公司 | Method for preparing PARP inhibitor, crystal form and application thereof |
WO2018157794A1 (en) * | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115138396A (en) * | 2021-03-30 | 2022-10-04 | 百济神州(苏州)生物科技有限公司 | Catalyst system for Sonogashira coupling reaction and in-situ ring closing reaction |
Also Published As
Publication number | Publication date |
---|---|
CN111171002B (en) | 2021-04-06 |
CN113402502A (en) | 2021-09-17 |
CN113402502B (en) | 2022-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108440330B (en) | Preparation method of doxycycline hydrochloride | |
CN107118207A (en) | The preparation method of one class CDK inhibitor | |
CN114573506B (en) | Drug intermediate and synthetic method thereof, isoquinoline derivative and synthetic method thereof | |
CN109641891B (en) | Novel compounds and methods | |
CN111171002B (en) | Preparation method of PARP inhibitor intermediate | |
CN104844602B (en) | A kind of preparation method of Li Gelieting | |
CN101973981A (en) | Refining method of 1-(5-isoquinoline sulfonyl) homopiperazine hydrochloride | |
CN105777617A (en) | Ceritinic synthesis intermediate and preparation method thereof | |
CN106632312A (en) | Apixaban related substance, intermediate, preparation method and applications thereof | |
CN112225729B (en) | Pyrimidine derivative, preparation method and application thereof and pharmaceutical composition | |
CN109020977B (en) | Preparation method of Acaraburtinib | |
CN102838586A (en) | Method for preparing lenalidomide | |
CN105801559B (en) | The preparation method of 4- methyl -3- [[4- (3- pyridyl group) -2- pyrimidine radicals] amino] ethyl benzoate | |
CN103896889B (en) | Lapatinib intermediate and its preparation method and application | |
CN112898277B (en) | Preparation method of afatinib intermediate | |
CN105198806A (en) | Method for synthesizing quinoline by aromatic amine and diketone | |
CN115138396A (en) | Catalyst system for Sonogashira coupling reaction and in-situ ring closing reaction | |
CN104974134B (en) | Refining method of imatinib mesylate | |
CN115141178A (en) | Method for preparing PARP inhibitor intermediate | |
CN107056781A (en) | A kind of synthetic method of the formaldoxime of (E) 5 methyl 1H pyrrolo-es [2,3 b] pyridine 3 | |
CN110903338B (en) | Sulfur-containing urea arsenic sugar with antitumor activity and preparation method and application thereof | |
CN105777616B (en) | Synthetic intermediate of Ceritinib and preparation method thereof | |
CN114920689B (en) | Preparation method of regorafenib intermediate | |
CN104583204A (en) | Process for the synthesis of substituted gamma lactams | |
CN107176948A (en) | The preparation of UD-CG115BS.acardi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |